Wadhwa Anant, Schaefer Sara M
Division of Movement Disorders, Department of Neurology, Yale School of Medicine, New Haven, CT, USA.
Tremor Other Hyperkinet Mov (N Y). 2019 Aug 1;9. doi: 10.7916/tohm.v0.681. eCollection 2019.
Primary orthostatic tremor (POT) remains a therapeutic conundrum. Various medication classes have been tried, yielding modest results at best.
A 62-year-old female with a 13-year history of POT, refractory to clonazepam up to 20 mg/day, was treated with perampanel 1-2 mg/day. She reported 90% subjective symptomatic improvement.
This case highlights the potential for use of perampanel, a novel AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist for the treatment of POT. There has been one prior report citing its use for POT with complete resolution of symptoms. We encourage further studies to highlight its efficacy for POT.
原发性直立性震颤（POT）仍然是一个治疗难题。已经尝试了各种药物类别，至多产生了适度的效果。
一名62岁女性，有13年POT病史，对高达20毫克/天的氯硝西泮治疗无效，接受了每日1 - 2毫克的吡仑帕奈治疗。她报告主观症状改善了90%。
本病例突出了吡仑帕奈（一种新型α-氨基-3-羟基-5-甲基-4-异恶唑丙酸（AMPA）受体拮抗剂）用于治疗POT的潜力。之前有一份报告引用了其用于POT并使症状完全缓解的情况。我们鼓励进一步开展研究以突出其对POT的疗效。
